INZY
Inozyme Pharma
INZY
INZY
Delisted
INZY was delisted on the 30th of June, 2025.
77 hedge funds and large institutions have $205M invested in Inozyme Pharma in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
4% more funds holding
Funds holding: 74 → 77 (+3)
1.37% more ownership
Funds ownership: 77.56% → 78.93% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
77
Holding in Top 10
1
Calls
$866K
Puts
$416K
Top Buyers
| 1 | +$13.6M | |
| 2 | +$13.1M | |
| 3 | +$7.21M | |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$6.56M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.41M |
Top Sellers
| 1 | -$9.16M | |
| 2 | -$3.69M | |
| 3 | -$1.61M | |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$982K |
| 5 |
Walleye Capital
New York
|
-$865K |